Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy

NCT00886743 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00886743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00886743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2009
Completion date
December 31, 2015
Enrollment
19 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

severe thrombocytopenia